GENFIT has announced a research collaboration with EVerZom to expand its Acute-On-Chronic Lier Failure (ACLF) research via exosome-based regenerative technology.

GENFIT and EVerZom plan to run exploratory studies to assess efficacy for EViv in ACLF, with a clear decision point within 18 months on whether to advance into clinical development.

Pascal Prigent, CEO, GENFIT, commented, “Through this collaboration, GENFIT has exclusive rights to explore a novel mechanism of action supporting organ repair, complementing our existing programmes G1090N, SRT-015 and CLM-022. Our shared objective is to rapidly generate proof-of-concept data to determine whether EViv confirms its potential for clinical development.”

Drug candidate EViv leverages a proprietary exosome platform to bring an innovative regenerative therapy approach to ACLF. In the case of, and following, positive in vivo proof-of-concept results, GENFIT has an exclusive option to take an exclusive licence in the field of liver disease to advance EViv into clinical development. The collaboration combines EVerZom’s exosome expertise with GENFIT’s leadership in ACLF, aiming to accelerate therapeutic progress.

Jeanne Volatron, CEO and Co-founder, EVerZom, added, “As a pioneer in the exosome field, our goal is to push the boundaries of gene and cell therapies and open new avenues for regenerative medicine. ACLF is a highly relevant indication for positioning our candidate EViv and this collaboration with GENFIT marks the first partnership for EViv in this indication. With GENFIT’s proven track record in advancing therapies in emerging areas and expertise in ACLF, we see it as the ideal partner to accelerate preclinical development and move toward the clinical stage.”

Exosomes are tiny biological vesicles (30 to 150 nanometers) naturally secreted by cells. They play a key role in intercellular communication, transporting proteins, messenger RNAs, and other functional biomolecules between cells. EVerZom leverages exosomes derived from mesenchymal stem cells, known for their regenerative and immunomodulatory properties. Compared to the cells themselves, exosomes offer numerous advantages: increased stability, reduced variability, enhanced patient safety, and simplified logistics (direct hospital storage and immediate availability).